Table 3.

Recommendations on the Management of Clozapine-Withdrawal-Induced Cholinergic Rebound

Recommendations	Type	Level of Evidence	Strength of Recommendation
Avoid abrupt discontinuation of clozapine to minimise risk of cholinergic rebound symptoms	Evidence-based	(III) evidence from non-experimental descriptive study	(C) Directly based on category III evidence
Consider an anticholinergic agent to treat cholinergic rebound symptoms	Evidence-based	(III) evidence from non-experimental descriptive study	(C) Directly based on category III evidence
Where feasible, reinitiate clozapine rather than switching to another antipsychotic	Evidence-based	(III) evidence from non-experimental descriptive study	(C) Directly based on category III evidence